IBDEI2MJ ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,1989,0)
 ;;=ADMINISTRATIVE TOPICS^2^159
 ;;^UTILITY(U,$J,358.4,1990,0)
 ;;=ANGINA^3^159
 ;;^UTILITY(U,$J,358.4,1991,0)
 ;;=ATHEROSCLEROSIS^4^159
 ;;^UTILITY(U,$J,358.4,1992,0)
 ;;=CARDIOVASCULAR^5^159
 ;;^UTILITY(U,$J,358.4,1993,0)
 ;;=DERMATOLOGY^9^159
 ;;^UTILITY(U,$J,358.4,1994,0)
 ;;=EAR DISORDERS^10^159
 ;;^UTILITY(U,$J,358.4,1995,0)
 ;;=EENT^11^159
 ;;^UTILITY(U,$J,358.4,1996,0)
 ;;=ENDOCRINE/METABOLIC^12^159
 ;;^UTILITY(U,$J,358.4,1997,0)
 ;;=EYE DISORDERS^13^159
 ;;^UTILITY(U,$J,358.4,1998,0)
 ;;=EYE INJURY^14^159
 ;;^UTILITY(U,$J,358.4,1999,0)
 ;;=GASTROENTEROLOGY^15^159
 ;;^UTILITY(U,$J,358.4,2000,0)
 ;;=GU/RENAL^16^159
 ;;^UTILITY(U,$J,358.4,2001,0)
 ;;=HEADACHE^17^159
 ;;^UTILITY(U,$J,358.4,2002,0)
 ;;=HEART FAILURE^18^159
 ;;^UTILITY(U,$J,358.4,2003,0)
 ;;=HEART VALVE DISEASE^19^159
 ;;^UTILITY(U,$J,358.4,2004,0)
 ;;=HEMATOLOGY/ONCOLOGY^20^159
 ;;^UTILITY(U,$J,358.4,2005,0)
 ;;=HISTORY OF ILLNESS^21^159
 ;;^UTILITY(U,$J,358.4,2006,0)
 ;;=INFECTIOUS DISEASE^22^159
 ;;^UTILITY(U,$J,358.4,2007,0)
 ;;=LIVER DISEASE^23^159
 ;;^UTILITY(U,$J,358.4,2008,0)
 ;;=MENTAL HEALTH^25^159
 ;;^UTILITY(U,$J,358.4,2009,0)
 ;;=MOVEMENT DISORDERS^26^159
 ;;^UTILITY(U,$J,358.4,2010,0)
 ;;=MUSCULOSKELETAL^27^159
 ;;^UTILITY(U,$J,358.4,2011,0)
 ;;=NEUROLOGY^28^159
 ;;^UTILITY(U,$J,358.4,2012,0)
 ;;=PAIN^29^159
 ;;^UTILITY(U,$J,358.4,2013,0)
 ;;=PREVENTIVE HEALTH^30^159
 ;;^UTILITY(U,$J,358.4,2014,0)
 ;;=PULMONARY^31^159
 ;;^UTILITY(U,$J,358.4,2015,0)
 ;;=SEXUAL TRAUMA^32^159
 ;;^UTILITY(U,$J,358.4,2016,0)
 ;;=SIGNS,SYMPTOMS,CONDITIONS^33^159
 ;;^UTILITY(U,$J,358.4,2017,0)
 ;;=SPRAIN/STRAIN-INITIAL ENCOUNTER^34^159
 ;;^UTILITY(U,$J,358.4,2018,0)
 ;;=SUBSTANCE DISORDERS^35^159
 ;;^UTILITY(U,$J,358.4,2019,0)
 ;;=VARICOSE VEINS^36^159
 ;;^UTILITY(U,$J,358.4,2020,0)
 ;;=WOMEN'S HEALTH^37^159
 ;;^UTILITY(U,$J,358.4,2021,0)
 ;;=WOUNDS-INITIAL ENCOUNTER^38^159
 ;;^UTILITY(U,$J,358.4,2022,0)
 ;;=COMA^7^159
 ;;^UTILITY(U,$J,358.4,2023,0)
 ;;=CAUSES OF INJURY^6^159
 ;;^UTILITY(U,$J,358.4,2024,0)
 ;;=DEMENTIA^8^159
 ;;^UTILITY(U,$J,358.4,2025,0)
 ;;=LONG TERM CURRENT DRUG THERAPY^24^159
 ;;^UTILITY(U,$J,358.4,2026,0)
 ;;=NEW PATIENT^2^160
 ;;^UTILITY(U,$J,358.4,2027,0)
 ;;=ESTABLISHED PATIENT^1^160
 ;;^UTILITY(U,$J,358.4,2028,0)
 ;;=CONSULTATIONS^3^160
 ;;^UTILITY(U,$J,358.4,2029,0)
 ;;=POST OP VISIT (GLOBAL)^4^160
 ;;^UTILITY(U,$J,358.4,2030,0)
 ;;=PENIS & SCROTUM^7^161
 ;;^UTILITY(U,$J,358.4,2031,0)
 ;;=URINARY TRACT DRAINAGE & IMAGING^9^161
 ;;^UTILITY(U,$J,358.4,2032,0)
 ;;=URODYNAMICS^10^161
 ;;^UTILITY(U,$J,358.4,2033,0)
 ;;=INJ & INTRAVESICAL MEDS^4^161
 ;;^UTILITY(U,$J,358.4,2034,0)
 ;;=CYSTOURETHROSCOPY^1^161
 ;;^UTILITY(U,$J,358.4,2035,0)
 ;;=PROSTATE BIOPSY & IMAGING^8^161
 ;;^UTILITY(U,$J,358.4,2036,0)
 ;;=NURSING PROCEDURES^6^161
 ;;^UTILITY(U,$J,358.4,2037,0)
 ;;=MISCELLANEOUS^5^161
 ;;^UTILITY(U,$J,358.4,2038,0)
 ;;=IMMUNIZATION ADMIN^2^161
 ;;^UTILITY(U,$J,358.4,2039,0)
 ;;=IMMUNIZATIONS^3^161
 ;;^UTILITY(U,$J,358.4,2040,0)
 ;;=BLADDER^3^162
 ;;^UTILITY(U,$J,358.4,2041,0)
 ;;=BENIGN NEOPLASIA-KIDNEY/URETER^1^162
 ;;^UTILITY(U,$J,358.4,2042,0)
 ;;=KIDNEY/URETER^5^162
 ;;^UTILITY(U,$J,358.4,2043,0)
 ;;=MALIGNANT NEOPLASMS^6^162
 ;;^UTILITY(U,$J,358.4,2044,0)
 ;;=COMPLICATIONS^4^162
 ;;^UTILITY(U,$J,358.4,2045,0)
 ;;=NEURO UROLOGY^7^162
 ;;^UTILITY(U,$J,358.4,2046,0)
 ;;=BENIGN NEOPLASM-PENIS^2^162
 ;;^UTILITY(U,$J,358.4,2047,0)
 ;;=SEXUAL DISORDERS^11^162
 ;;^UTILITY(U,$J,358.4,2048,0)
 ;;=PENILE CONDITIONS^8^162
 ;;^UTILITY(U,$J,358.4,2049,0)
 ;;=POST OPERATIVE COMPLICATIONS^9^162
